Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.24
BCRX's Cash to Debt is ranked higher than
65% of the 1256 Companies
in the Global Biotechnology industry.

( Industry Median: 47.96 vs. BCRX: 4.24 )
BCRX' s 10-Year Cash to Debt Range
Min: 0.94   Max: 11087.67
Current: 4.24

0.94
11087.67
Equity to Asset 0.61
BCRX's Equity to Asset is ranked higher than
70% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BCRX: 0.61 )
BCRX' s 10-Year Equity to Asset Range
Min: -0.23   Max: 0.98
Current: 0.61

-0.23
0.98
F-Score: 4
Z-Score: 3.83
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -197.28
BCRX's Operating margin (%) is ranked higher than
67% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -76.30 vs. BCRX: -197.28 )
BCRX' s 10-Year Operating margin (%) Range
Min: -17879.61   Max: -18.42
Current: -197.28

-17879.61
-18.42
Net-margin (%) -207.94
BCRX's Net-margin (%) is ranked higher than
66% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. BCRX: -207.94 )
BCRX' s 10-Year Net-margin (%) Range
Min: -17170.39   Max: -18.03
Current: -207.94

-17170.39
-18.03
ROE (%) -114.48
BCRX's ROE (%) is ranked higher than
58% of the 1151 Companies
in the Global Biotechnology industry.

( Industry Median: -34.30 vs. BCRX: -114.48 )
BCRX' s 10-Year ROE (%) Range
Min: -544.61   Max: -8.43
Current: -114.48

-544.61
-8.43
ROA (%) -45.87
BCRX's ROA (%) is ranked higher than
66% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -26.94 vs. BCRX: -45.87 )
BCRX' s 10-Year ROA (%) Range
Min: -67.46   Max: -7.68
Current: -45.87

-67.46
-7.68
ROC (Joel Greenblatt) (%) -13674.69
BCRX's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1234 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. BCRX: -13674.69 )
BCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6910.46   Max: -43.48
Current: -13674.69

-6910.46
-43.48
Revenue Growth (3Y)(%) -39.50
BCRX's Revenue Growth (3Y)(%) is ranked higher than
63% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. BCRX: -39.50 )
BCRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 430.1
Current: -39.5

0
430.1
EBITDA Growth (3Y)(%) -14.10
BCRX's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. BCRX: -14.10 )
BCRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -41.9   Max: 64.5
Current: -14.1

-41.9
64.5
EPS Growth (3Y)(%) -10.20
BCRX's EPS Growth (3Y)(%) is ranked higher than
74% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. BCRX: -10.20 )
BCRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -38.4   Max: 52.9
Current: -10.2

-38.4
52.9
» BCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BCRX Guru Trades in

BCRX Guru Trades in

Q1 2014

BCRX Guru Trades in Q1 2014

Jim Simons 90,514 sh (New)
George Soros 59,700 sh (New)
» More
Q2 2014

BCRX Guru Trades in Q2 2014

Jim Simons Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$7.37 - $12.52 $ 10.185%0
George Soros 2014-03-31 New Buy0.01%$7.6 - $12.83 $ 10.18-4%59700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.80
BCRX's P/B is ranked higher than
67% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 6.38 vs. BCRX: 8.80 )
BCRX' s 10-Year P/B Range
Min: 1.04   Max: 122.5
Current: 8.8

1.04
122.5
P/S 32.90
BCRX's P/S is ranked higher than
73% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 28.95 vs. BCRX: 32.90 )
BCRX' s 10-Year P/S Range
Min: 0.73   Max: 2000
Current: 32.9

0.73
2000
EV-to-EBIT -17.77
BCRX's EV-to-EBIT is ranked higher than
86% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BCRX: -17.77 )
BCRX' s 10-Year EV-to-EBIT Range
Min: -41.9   Max: 0.7
Current: -17.77

-41.9
0.7
Current Ratio 2.71
BCRX's Current Ratio is ranked higher than
64% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. BCRX: 2.71 )
BCRX' s 10-Year Current Ratio Range
Min: 2.01   Max: 39.53
Current: 2.71

2.01
39.53
Quick Ratio 2.71
BCRX's Quick Ratio is ranked higher than
66% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. BCRX: 2.71 )
BCRX' s 10-Year Quick Ratio Range
Min: 2   Max: 39.53
Current: 2.71

2
39.53
Days Sales Outstanding 63.10
BCRX's Days Sales Outstanding is ranked higher than
82% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 115.94 vs. BCRX: 63.10 )
BCRX' s 10-Year Days Sales Outstanding Range
Min: 44.54   Max: 72039.47
Current: 63.1

44.54
72039.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.00
BCRX's Price/Net Cash is ranked higher than
82% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 55.00 vs. BCRX: 10.00 )
BCRX' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 315
Current: 10

0.61
315
Price/Net Current Asset Value 9.60
BCRX's Price/Net Current Asset Value is ranked higher than
82% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 31.07 vs. BCRX: 9.60 )
BCRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 191
Current: 9.6

0.61
191
Price/Tangible Book 8.80
BCRX's Price/Tangible Book is ranked higher than
72% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. BCRX: 8.80 )
BCRX' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 121.33
Current: 8.8

0.33
121.33
Price/Median PS Value 4.40
BCRX's Price/Median PS Value is ranked higher than
69% of the 1352 Companies
in the Global Biotechnology industry.

( Industry Median: 2.32 vs. BCRX: 4.40 )
BCRX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 122.25
Current: 4.4

0.12
122.25
Earnings Yield (Greenblatt) -5.80
BCRX's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1236 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. BCRX: -5.80 )
BCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -5.8   Max: 1563.9
Current: -5.8

-5.8
1563.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BO1.Germany,
Biocryst Pharmaceuticals Inc. is a Delaware corporation originally founded in 1986. The Company is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. It uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include Peramivir, BCX4161, Two 2nd generation HAE compounds, BCX4430, Forodesine and Ulodesine. Peramivir is a neuraminidase inhibitor for the treatment of patients with influenza and a potent, intravenously administered antiviral agent that rapidly delivers high plasma concentrations to the sites of infection. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention of attacks in patients with Hereditary Angioedema. Forodesine is a PNP inhibitor in development as a treatment for cancer. Ulodesine is a PNP inhibitor developed as a once-daily oral, chronic treatment for gout. The Company's product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
comment on BCRX Mar 02 2013 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Our Partners
3 Biotechs Looking Good this Earnings Season - Earnings ESP Jan 30 2015 - ZACKS

More From Other Websites
3 Biotechs Looking Good this Earnings Season - Earnings ESP Jan 30 2015
Equity markets ended little changed... Jan 26 2015
Special FDA designation puts more wind behind BioCryst's sails Jan 26 2015
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 26 2015
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary Angioedema Jan 26 2015
Strength Seen in Egalet (EGLT): Stock Soars 23.9% - Tale of the Tape Jan 23 2015
UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog Jan 22 2015
Flamel Technologies (FLML) in Focus: Stock Gains 15.4% - Tale of the Tape Jan 19 2015
BioCryst's BCX4161 Recommended for Orphan Drug in EU - Analyst Blog Jan 15 2015
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 14 2015
BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment... Jan 14 2015
BioCryst shares rally on positive opinion from Europe for angioedema drug Jan 14 2015
BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment... Jan 14 2015
Chimerix tackles Ebola outbreak Jan 13 2015
BioCryst to Present at J.P. Morgan Healthcare Conference Jan 06 2015
BioCryst to Present at J.P. Morgan Healthcare Conference Jan 06 2015
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2015
BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer Jan 05 2015
BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer Jan 05 2015
BioCryst Hits Trifecta For Flu, Ebola, and Hereditary Angioedema Dec 26 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK